Nintedanib and pirfenidone combo tied to less decline in FVC compared with monotherapy in IPF Dr. Shravani Dali1 Nov 2023 12:00 PM ISTNintedanib and pirfenidone combo well tolerated and tied to less decline in FVC compared with monotherapy in IPF suggests a new study published in the...
Antifibrotics improve quality of life in idiopathic pulmonary fibrosis: Study Dr. Kamal Kant Kohli28 Oct 2022 8:15 PM ISTDENMARK: In terms of enhancing survival, treatment with nintedanib and pirfenidone was preferred to no antifibrotic medication, regardless of the...
Conduct Active Surveillance Study: CDSCO Panel tells Cipla on Idiopathic Pulmonary Fibrosis Drug Pirfenidone tablet Dr. Divya Colin13 Oct 2022 6:00 PM ISTNew Delhi: Denying the pharma major Cipla's request for waiver of an active surveillance study, the Subject Expert Committee (SEC) functional under...
Cipla gets CDSCO panel nod for BE study of idiopathic pulmonary fibrosis drug Pirfenidone Medical Dialogues Team7 Sept 2021 2:59 PM ISTNew Delhi: Pharmaceutical major, Cipla has got a go-ahead from the Subject Expert Committee (SEC) of the Central Drugs Standard Control Organization...
Pirfenidone found safe, efficacious in idiopathic pulmonary fibrosis Dr. Kamal Kant Kohli19 May 2020 6:00 PM ISTPirfenidone has been found safe, and efficacious in idiopathic pulmonary fibrosis (IPF) in a real-world cohort study.Pirfenidone is an antifibrotic...
